Suchergebnisse - "Ryoo, Baek-Yeol"

PubPharm (504)

1

Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma

enthalten in: ResearchSquare.com | 2024

von Yoon, H. | Shin, Y. | Ryoo, B. | +17

2

Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma

enthalten in: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al. | 2024

von Yoon, H. | Shin, Y. | Ryoo, B. | +17

3

Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment

enthalten in: Journal of hepatology | 2024

von Chan, S. | Ryoo, B. | Mo, F. | +7

4

Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer

enthalten in: International journal of surgery (London, England) | 2024

von Lee, W. | Oh, M. | Kim, J. | +16

5

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma : the phase 2 RENOBATE trial

enthalten in: Nature medicine | 2024

von Kim, H. | Jung, S. | Lim, H. | +16

6

Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study

enthalten in: Cancer | 2024

von Piscaglia, F. | Ikeda, K. | Cheng, A. | +8

7

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

8

Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial

enthalten in: ResearchSquare.com | 2024

von Yoo, C. | Kim, H. | Jung, S. | +12

9

Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors

enthalten in: Scientific reports | 2024

von Kim, J. | Kim, J. | Kim, Y. | +6

10

Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour

enthalten in: EJNMMI physics | 2024

von Ha, S. | Kim, Y. | Oh, J. | +3

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[51]